Among Patients With Cancer And Invasive Fungal Infections, Hypoalbuminemia Linked To Increased Risk Of Subtherapeutic Posaconazole Plasma Levels, Study Finds

Infectious Disease Advisor (5/29) reports, “In patients with cancer receiving delayed-release posaconazole for the treatment of invasive fungal infections (IFIs), hypoalbuminemia is associated with increased risk for subtherapeutic posaconazole plasma levels, according to findings published in Open Forum Infectious Diseases.” In the study, “an ideal body weight at or above 60 kg and hypoalbuminemia (albumin, ≤3 g/dL) were significantly associated with subtherapeutic posaconazole levels.”